These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 12672279)

  • 1. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
    Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
    Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
    Nagpal S
    Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
    Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
    Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Gliadel wafers in the treatment of high-grade gliomas.
    Bregy A; Shah AH; Diaz MV; Pierce HE; Ames PL; Diaz D; Komotar RJ
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1453-61. PubMed ID: 24236823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
    Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
    J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
    Sabel M; Giese A
    Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
    Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
    Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
    Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
    No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management in the treatment of malignant gliomas with BCNU wafer implants.
    Giese A; Bock HC; Kantelhardt SR; Rohde V
    Cent Eur Neurosurg; 2010 Nov; 71(4):199-206. PubMed ID: 20063259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
    Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
    Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
    Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
    World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
    Hammoud DA; Belden CJ; Ho AC; Dal Pan GJ; Herskovits EH; Hilt DC; Brem H; Pomper MG
    AJR Am J Roentgenol; 2003 May; 180(5):1469-75. PubMed ID: 12704070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
    Murai S; Ichikawa T; Kurozumi K; Shimazu Y; Oka T; Otani Y; Shimizu T; Date I
    J Clin Neurosci; 2016 Nov; 33():148-153. PubMed ID: 27452129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
    Limentani SA; Asher A; Heafner M; Kim JW; Fraser R
    J Neurooncol; 2005 May; 72(3):241-4. PubMed ID: 15937647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
    Kleinberg L
    Core Evid; 2012; 7():115-30. PubMed ID: 23118709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.